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Abstract
Background: Although infrequent, some rheumatoid arthritis (RA) patients achieve disease-modifying antirheumatic
drug (DMARD)-free sustained remission. The absence of RA-specific autoantibodies, such as anticitrullinated protein
antibodies (ACPA), is known to be associated with this outcome but further mechanisms underlying the chronic nature
of RA are largely unknown. Magnetic resonance imaging (MRI)-detected bone marrow edema (BME), or osteitis,
strongly predicts erosive progression and is associated with ACPA positivity. Therefore, we hypothesized that the
presence of MRI-detected osteitis is also predictive of not achieving DMARD-free sustained remission and that the
presence of osteitis mediates the association between ACPA and DMARD-free sustained remission.
Methods: A 1.5 T unilateral hand and foot MRI was performed at disease presentation in 238 RA patients, evaluating
BME, synovitis, and tenosynovitis (summed as MRI inflammation score). DMARD-free sustained remission, defined as the
absence of clinical synovitis after DMARD cessation that persisted during the total follow-up, was assessed (median
follow-up 3.8 years). Associations between the different MRI-detected inflammatory features and this outcome were
studied. A mediation analysis was performed to study whether the presence of BME mediated the association between
ACPA and DMARD-free sustained remission. Finally, patterns of MRI-detected inflammation with regard to DMARD-free
sustained remission were studied using partial least squares (PLS) regression.
Results: Forty-six (19.3%) patients achieved DMARD-free sustained remission. ACPA positivity associated independently
with remission (hazard ratio (HR) 0.16, 95% confidence interval (CI) 0.06–0.39). In contrast, no associations were observed
between MRI-detected BME (HR 0.99, 95% CI 0.94–1.03), or other MRI inflammatory features, and achieving DMARD-free
sustained remission. Thus, the presence of BME did not mediate the association between ACPA and DMARD-free sustained
remission. Furthermore, a PLS analysis revealed that patients who did or did not achieve remission could not be
distinguished by patterns of MRI-detected inflammation.
Conclusions: At disease presentation, osteitis, as well as other MRI-detected inflammatory features, was not
associated with achieving DMARD-free sustained remission over time. Thus, imaging predictors for joint damage
and disease persistence differ. The processes mediating RA chronicity remain largely unsolved.
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Background
As joint damage is becoming less prevalent in patients
with rheumatoid arthritis (RA), the focus is shifting to
other disease outcomes such as disease-modifying anti-
rheumatic drug (DMARD)-free sustained remission [1].
DMARD-free sustained remission means that DMARDs
can be discontinued without the recurrence of clinical
synovitis [1, 2]. Thanks to improved treatment strategies,
DMARD-free sustained remission is more feasible and
corresponds with perceived normalization of physical
functioning and pain, fatigue, and stiffness levels for
patients [1, 3].
Pathophysiological mechanisms behind RA chronicity
or, the opposite, DMARD-free sustained remission are
largely unknown [4]. Short symptom duration at disease
presentation has been shown to be predictive suggesting
that the timing of disease modification is important [1,
2, 5]. The strongest predictor for DMARD-free sustained
remission is the absence of RA-specific autoantibodies,
such as anticitrullinated protein antibodies (ACPA) [1, 2].
This suggests that patients who can achieve this outcome
are inherently different.
Joint destruction and not achieving DMARD-free
sustained remission are both characteristics of a severe
disease course. Therefore, hypothetically, predictors for
both outcomes are similar. ACPA are such an example.
However, local joint inflammation, measured using the
swollen joint count (SJC), while predictive for erosive
progression [6, 7], was not predictive for DMARD-free
sustained remission [1, 2]. A more sensitive method to
detect local inflammation is magnetic resonance imaging
(MRI). In addition to synovitis and tenosynovitis, MRI
can detect bone marrow edema (BME), also called oste-
itis. Osteitis is not specific for RA as it has also been
observed in other conditions such as psoriatic arthritis
and in symptom-free controls [8–10]. In RA, the pres-
ence of osteitis is strongly predictive for erosive progres-
sion, with odds ratios reported up to 60 [8, 11–13]. The
process of joint destruction is likely to be ACPA-driven
since ACPA-positive RA patients have higher osteitis
scores [14, 15]. Furthermore, ACPA have been shown to
be able to induce osteoclastogenesis leading to subse-
quent bone loss [16] and a histologic study of bone
samples in which MRI-detected osteitis is present revealed
an increased presence of osteoclasts compared with con-
trol samples [17]. Thus, osteitis appears to be a mediator
in the link between ACPA and erosive progression.
Our ultimate aim is to increase the understanding of
processes involved in achieving DMARD-free sustained
remission or disease chronicity. With the underlying as-
sumption that predictors for erosive progression and not
achieving DMARD-free sustained remission are similar,
we hypothesized that the presence of osteitis at disease
presentation also associates with a decreased chance of
achieving DMARD-free sustained remission. Furthermore,
we hypothesized that the association between ACPA and
DMARD-free sustained remission is mediated by osteitis.
To evaluate these hypotheses, associations between MRI-
detected inflammation and DMARD-free sustained remis-
sion were evaluated and a mediation analysis was per-
formed. Finally, to study not only the presence of osteitis
itself, but also its relationship with other types of MRI-
detected inflammation, and its location, and achieving
DMARD-free sustained remission, we looked at whether a
pattern of MRI-detected inflammation (covering the type
of MRI inflammatory feature, severity, and location) could




The Leiden Early Arthritis Clinic (EAC) is a population-
based inception cohort that includes patients with clinic-
ally confirmed synovitis of ≥ 1 joint and a symptom
duration of < 2 years [18]. Between August 2010 and
September 2014 an MRI was performed at baseline in
598 consecutive patients. Of these patients, 275 fulfilled
the 1987 and/or 2010 criteria for RA and were treated
with DMARDs during the first year. Thirty-seven pa-
tients were excluded (22 because they never received
DMARD therapy despite fulfilling classification criteria,
4 because the MRI was performed without contrast, and
11 because of participation in a trial with initial biologic
therapy that differed from routine care) [19, 20]. Thus,
in total 238 RA patients were studied (Fig. 1). According
to local and national guidelines, RA patients were initially
treated with methotrexate (started at or after the 2-week
visit); after failure, another conventional DMARD was
initiated or added. Biologicals were allowed after failure of
> 2 conventional DMARDs and were used in 22 patients
(9%) of whom none achieved DMARD-free sustained re-
mission. Treatment was steered by disease activity score
(DAS). All patients had scheduled EAC visits at 4 months,
8 months, 12 months, 18 months, 24 months, and then
yearly. Besides these visits, regular visits were planned
when deemed necessary by either the patient or rheuma-
tologist (usually every 3–4 months). All patients provided
written informed consent. The study was approved by the
local medical ethical committee.
MRI
A unilateral 1.5 T MRI of the metacarpophalangeal
(MCP; 2–5) joints, wrist, and metatarsophalangeal
(MTP; 1–5) joints of the most painful side or, in case of
equally severe symptoms, of the dominant side was
made < 2 weeks after inclusion. MRIs were scored on
BME and synovitis in line with the RA MRI scoring
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(RAMRIS) method [21] and on tenosynovitis according
to Haavardsholm et al. [22]. The total MRI inflammation
score was the sum of total BME, synovitis, and teno-
synovitis scores. MRIs were scored by two experienced
readers (intraclass correlation coefficient (ICC) 0.94)
who were blinded to clinical data. The mean scores of
the two readers were taken. More information about
the MRI scanning protocol and scoring method has
been described previously [10, 23, 24] and is provided
in Additional file 1 (Supplementary methods).
DMARD-free sustained remission
Medical records of all patients were reviewed in April
2017 for the presence of DMARD-free sustained remis-
sion, defined as the absence of clinical synovitis that
persisted after cessation of DMARDs during the total
subsequent follow-up. The follow-up duration after
DMARD cessation had to be ≥ 1 year to fulfill the defin-
ition. The date of remission was the date 1 year after
DMARD cessation. For patients not achieving remission,
the date of censoring was the date of reviewing the
medical records or an earlier date in case patients were
lost to follow-up.
Statistical analysis
Associations between baseline characteristics, including
MRI-detected inflammatory features and DMARD-free
sustained remission, were assessed using univariable and
multivariable Cox regression analyses. Partial least
squares (PLS) regression was used to study whether cer-
tain patterns of MRI-detected inflammation discrimi-
nated between patients who did and did not achieve
remission. This was done since not only the single pres-
ence of BME but also information on its presence in
combination with other MRI-detected inflammatory
features, or the location of BME, could be discrimina-
tive. Previous studies observed that BME is often present
in certain carpal bones of symptom-free controls (such
as the lunate) which may be caused by mechanical
factors, and suggests that the location of BME can be
relevant for the interpretation [10]. PLS regression clus-
ters features and locations of MRI-detected inflamma-
tion that frequently occur together into factors, and
presents for each factor the variance in the outcome that
is explained by this factor. These factors can then be
plotted against each other to look for clustering. A medi-
ation analysis was performed according to Baron and
Kenny [25]. Detailed statistical information is provided
in Additional file 1. SPSS V.23.0 software was used.
Results
Patient characteristics
Of the 238 studied patients, 46 (19.3%) achieved
DMARD-free sustained remission after a median dur-
ation of 2.8 (interquartile range (IQR) 2.0–3.5) years. For
patients who did not achieve DMARD-free sustained re-
mission, the median follow-up duration was 3.8 (IQR
3.0–5.0) years. Table 1 presents the baseline characteris-
tics. The majority of patients were female and the mean
age was 57 years. Associations between clinical charac-
teristics and achieving DMARD-free sustained remission
are shown in Table 2. Only the presence of ACPA was
independently associated (hazard ratio (HR) 0.16, 95%
confidence interval (CI) 0.06–0.39) with DMARD-free
sustained remission.
Association between MRI-detected inflammatory features
and DMARD-free sustained remission
The MRI-detected BME score was not associated with
achieving DMARD-free sustained remission (HR 0.99,
95% CI 0.94–1.03). This was the same for MRI-detected
synovitis (HR 1.03, 95% CI 0.97–1.09), tenosynovitis (HR
1.04, 95% CI 0.99–1.10), and the total MRI inflammation
score (HR 1.01, 95% CI 0.99–1.03) (Table 3). Also, in
multivariable models where corrections were made for the
simultaneous presence of other inflammatory features and
ACPA, BME was not associated with remission (Table 3).
Fig. 1 Flowchart of patient selection. DMARD disease modifying
antirheumatic drug, EAC early arthritis clinic, MRI magnetic resonance
imaging, RA rheumatoid arthritis
Burgers et al. Arthritis Research & Therapy  (2018) 20:68 Page 3 of 8
Mediation analysis revealed that BME did not mediate the
association between ACPA and DMARD-free sustained
remission (Fig. 2).
Patterns of MRI-detected inflammation
Finally, we questioned whether a combination of features
(covering the inflammatory features, the severity, and
the location of MRI-detected inflammation), not a single
inflammatory feature, was able to distinguish between
patients who did and did not achieve DMARD-free
sustained remission. Using PLS, two factors were identi-
fied that together explained 15.0% of the variance. When
these factors were plotted against each other, no clear
clusters were observed. Thus, no patterns of MRI-
detected inflammation were identified that were associ-
ated with achieving DMARD-free remission (Fig. 3).
Discussion
Mechanisms underlying (the resolution of ) the chronic
nature of RA are scarcely understood. Moreover, there
are few known predictors for DMARD-free sustained
remission. Although MRI-detected inflammation, and
osteitis in particular, is a potent predictor for erosive
progression [8, 11, 13], this imaging marker was not
predictive for DMARD-free sustained remission.
Table 1 Baseline clinical and MRI characteristics of all patients and separately for patients that have and have not achieved DMARD-
free sustained remission
All patients (n = 238) DMARD-free sustained remission (n = 46) No remission (n = 192)
Clinical characteristics
Age in years, mean (SD) 57 (14) 62 (13) 55 (14)
Female gender, n (%) 157 (66) 28 (61) 129 (67)
Symptom duration in weeks 15 (7–32) 14 (5–21) 17 (7–34)
Symptom duration > 12 weeks, n (%) 100 (42) 20 (44) 80 (42)
HAQ score, mean (SD) 0.9 (0.6) 1.1 (0.5) 1.0 (0.9)
68-TJC 8 (4–14) 9 (5–17) 8 (4–13)
66-SJC 5 (2–10) 8 (3–13) 5 (2–10)
CRP mg/L 9 (3–21) 17 (9–27) 8 (3–20)
ESR mm/h, mean (SD) 30 (24) 33 (25) 29 (24)
ACPA-positive, n (%) 120 (50) 6 (13) 114 (59)
RF-positive, n (%) 140 (59) 16 (35) 124 (65)
MRI characteristics
BME score 3.5 (1.0–8.0) 4.0 (1.4–7.3) 3.5 (1.0–8.5)
Synovitis score 5.0 (2.5–9.5) 7.3 (3.0–10.0) 4.5 (2.5–9.5)
Tenosynovitis score 4.0 (1.5–7.5) 4.5 (1.8–9.3) 4.0 (1.5–7.0)
Total MRI inflammation score 13.5 (6.5–26.0) 16.5 (6.4–27.6) 12.5 (6.5–25.5)
All values are shown as median (interquartile range) unless indicated otherwise
Values are missing as follows (n): symptom duration (2), HAQ (13), TJC (11), SJC (12), and ESR (2)
ACPA anticitrullinated protein antibodies, BME bone marrow edema, CRP C-reactive protein, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation
rate, HAQ health assessment questionnaire, MRI magnetic resonance imaging, RF rheumatoid factor, SD standard deviation; SJC swollen joint count, TJC tender joint count
Table 2 Results of univariable and multivariable Cox regression
analyses of clinical baseline characteristics in relation to






Age in years 1.04 (1.02–1.07)* 1.02 (0.99–1.04)
Female gender 0.81 (0.45–1.47)
Symptom duration > 12 weeks 0.83 (0.46–1.50)
HAQ score 1.11 (0.69–1.78)
68-TJC 1.02 (0.98–1.05)
66-SJC 1.06 (1.02–1.10)* 1.03 (0.99–1.08)
CRP mg/L 1.01 (1.0–1.02)* 1.00 (0.99–1.01)
ESR mm/h 1.01 (1.0–1.02)
ACPA-positive 0.12 (0.05–0.27)* 0.16 (0.06–0.39)*
RF-positive 0.33 (0.18–0.61)* 0.80 (0.41–1.6)
ACPA anticitrullinated protein antibodies, CI confidence interval, CRP C-reactive
protein, DMARD disease-modifying antirheumatic drug, ESR erythrocyte
sedimentation rate, HAQ health assessment questionnaire, HR hazard ratio, RF
rheumatoid factor, SJC swollen joint count, TJC tender joint count
*p < 0.05
aThe multivariable model includes all variables that showed a significant
association with sustained DMARD-free remission in univariable Cox regression
analyses. A total of 224 patients were included in the multivariable model since data
on the tested variables were incomplete for 14 patients. No statistically significant
differences were present between patients with missing data and the
patient included in the multivariable model (data not shown)
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The absence of this association was surprising since
ACPA has been associated with higher osteitis scores
[14, 15] and less DMARD-free sustained remission [2].
Although our data showed an association between
ACPA and osteitis, there was no association between
osteitis and achieving DMARD-free sustained remission.
Therefore, osteitis did not mediate the association of
ACPA with DMARD-free sustained remission (Fig. 2).
Thus, the studied imaging predictors for erosive
progression and RA chronicity differed. Previous studies
on genetic factors also showed that, although IL2RA and
HLA-DRB1-encoding shared epitope alleles were risk
factors for both outcomes, the majority of genetic factors as-
sociated with erosive progression were not associated with
RA persistence [26, 27]. Together, this suggests that patho-
physiological mechanisms underlying erosive progression
and RA persistence are different. Thus, our main hypoth-
esis, namely that imaging predictors for both outcomes are
similar, is likely unjust. So far, only the absence of autoanti-
bodies and short symptom duration have been shown to be
predictive for DMARD-free sustained remission. Besides
these factors, there are probably other, yet unknown, host
and environmental factors that play pivotal roles in pro-
cesses underlying disease resolution.
This study evaluated MRI-detected inflammation at
diagnosis in relation to achieving DMARD-free sus-
tained remission over time. Thus, the hypothesis that
was tested presumed that patients that achieved remis-
sion were already different in respect to joint inflamma-
tion in an early, DMARD-naive disease phase. Our study
did not contain longitudinal MRI data. Although we pre-
viously observed that osteitis is often a persisting feature
[6], we did not perform an MRI at the time of remission.
Others observed, in DMARD-treated patients in DAS
remission, that residual inflammation was present in the
majority of patients (up to 96% for synovitis) [28–30].
The clinical relevance of residual inflammation is
unclear, although it is suggested that its presence in
patients that still receive DMARD treatment is associ-
ated with ongoing erosive progression [30]. While our
Table 3 Associations between MRI-detected inflammation and achieving DMARD-free sustained remission over time
Type of MRI-detected inflammation Univariable model HR (95% CI) Multivariable model 1a HR (95% CI) Multivariable model 2b HR (95% CI)
BME 0.99 (0.94–1.03) 0.96 (0.99–1.02) 1.00 (0.94–1.07)
Synovitis 1.03 (0.97–1.09) 1.04 (0.95–1.15) 1.00 (0.90–1.10)
Tenosynovitis 1.04 (0.99–1.10) 1.03 (0.95–1.11) 1.01 (0.94–1.08)
Total inflammation 1.01 (0.99–1.03) – –
All HRs are per point increase of MRI-detected inflammation
BME bone marrow edema, CI confidence interval, DMARD disease-modifying antirheumatic drug, HR hazard ratio, MRI magnetic resonance imaging
aMultivariable model 1 includes MRI-detected BME, synovitis and tenosynovitis
bMultivariable model 2 includes MRI-detected BME, synovitis and tenosynovitis as well as ACPA
Fig. 2 Schematic overview of the causal path between ACPA and DMARD-free sustained remission that was studied using a mediation model as
described by Baron and Kenny [25]. According to the Baron and Kenny model there are three requirements for a true mediation relationship. The
first step is to regress the dependent variable on the independent variable to confirm that the independent variable is predictive for the dependent variable.
In our data, the absence of anticitrullinated protein antibodies (ACPA) was indeed predictive for disease-modifying antirheumatic drug (DMARD)-free sustained
remission (HR 0.16, p < 0.001). The second step is to regress the mediator variable on the independent variable to confirm that the independent variable is a
predictor of the mediator. The association between ACPA and bone marrow edema (BME) was not statistically significant although there
was a strong tendency towards significance (β = 1.58, p = 0.055). The final step would be to regress the dependent variable on both the
mediator and independent variable to confirm that the mediator is a significant predictor of the dependent variable and the effect of
the independent variable from the first step is greatly reduced. This was not the case (HR for ACPA corrected for BME 0.12, p < 0.001).
As shown in Table 2, BME scores were not associated with DMARD-free sustained remission (HR 0.99, p = 0.56). Thus, this mediation analysis revealed
that magnetic resonance imaging (MRI)-detected BME does not mediate the association of ACPA with not achieving DMARD-free sustained remission
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definition of remission was stricter than those used in
the cited studies, we do not know whether MRI-
detected synovitis is present in patients that achieved
DMARD-free sustained remission. Low-grade synovitis
has also been observed in symptom-free patients [10]
and, as our defined status of sustained DMARD-free re-
mission corresponds with normalized levels of function,
fatigue, and pain [1, 3], it is questionable if remaining
MRI-detected synovitis, if present after having achieved
DMARD-free sustained remission, is clinically relevant.
Patients included in this study fulfilled either the 1987
and/or 2010 criteria for RA. If not used correctly, the 2010
criteria could lead to misclassification of patients with RA,
thereby influencing the study results [31]. To prevent mis-
classification, the classification criteria were used as
intended, namely only in patients with a clinical (suspected)
diagnosis of RA. Furthermore, patients who never received
DMARD therapy were excluded (Fig. 1). When analyses
were repeated in patients fulfilling the 1987 criteria for RA
(n = 186), results remained similar (data not shown).
However, this association was not significant in multi-
variable analysis was surprising as this was not observed
in two previous studies [1, 2]. However, this association
was significant in multivariable analysis. Since local in-
flammation measured by sensitive imaging was also not
associated with DMARD-free remission, the overall con-
clusion is that the extent of local inflammation at first
presentation is not related to the likelihood of achieving
DMARD-free remission.
One limitation of our study is that, despite applying a
stringent definition of remission where clinical synovitis
had to be absent ≥ 1 year after DMARD cessation, the
available follow-up might be insufficient to detect flares
after several years of follow-up. Another limitation is the
sample size; although large for an MRI study, it is un-
known if results would have been different in an even
larger dataset. However, there was not even a tendency
towards an association between BME and remission.
A strength of this study is that the data were obtained in
a center in which DAS-steered treatment regimens imply
that in case of DAS < 2.4 DMARDs are tapered and subse-
quently stopped. This strategy contributed to the relative
high percentage of patients (19%) that achieved DMARD-
free sustained remission. Other studies with varying follow-
up durations reported ranges of DMARD-free remission
between 3.6% and 22% [4]. Nonetheless, despite local pro-
tocols, rheumatologists had the freedom not to taper medi-
cation in patients in DAS remission. Therefore, it is
possible that the current percentage is an underestimation.
Conclusions
In conclusion, the presence of MRI-detected osteitis at
the time of presentation with RA, although shown to be
strongly predictive for erosive progression, was not asso-
ciated with lower hazards on achieving DMARD-free
sustained remission. Additionally, the current data dem-
onstrate that MRI is not helpful in identifying patients
who can achieve DMARD-free sustained remission over
time. Finally, although acknowledging that the processes
involved in joint damage are different from those medi-
ating RA chronicity, the pathophysiology of the latter re-
mains elusive.
Fig. 3 A combination of MRI features (covering type, location, and severity of inflammation) did not cluster RA patients who did or did not achieve
DMARD-free sustained remission over time. This figure depicts the results of a PLS regression analysis. Two factors were identified that together explained
15.0% of the explained variance between patients who did and did not achieve DMARD-free sustained remission over time. Individual patient scores on
factor 1 (y axis) and factor 2 (x axis) are plotted against each other. The figure reveals that there is overlap, which means that there are no clear patterns
of MRI-detected inflammation that discriminated between patients who did and did not achieve DMARD-free sustained remission
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